Ionis Pharmaceuticals is driving progress in antisense technology, demonstrating meaningful advances in genetic disease treatment
Ionis Pharmaceuticals is driving progress in antisense technology, demonstrating meaningful advances in genetic disease treatment
New partnerships and funding rounds are powering the rapid growth of RNA therapeutics.
Moderna pushes the boundaries of mRNA therapy into rare genetic diseases, aiming for transformative treatments.
Manufacturing breakthroughs are set to transform cell therapy production, paving the way for faster trials and wider patient …
AI-driven drug discovery is accelerating innovation and transforming biopharma R&D.
Australia’s National Genomic Registry is connecting patients, clinicians, and researchers to transform rare disease care in real time.
Australian-led clinical trials are advancing the future of diabetes care with oral insulin innovations.
New partnerships in real-time genomics promise faster, more accurate diagnoses for pediatric rare diseases.
A promising vaccine candidate advances efforts to combat neglected tropical diseases with mRNA innovation.
Partnership targets Alzheimer’s and Parkinson’s with novel delivery platforms and precision medicine approaches.
Already a subscriber? Log in